334 related articles for article (PubMed ID: 32712650)
1. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
[TBL] [Abstract][Full Text] [Related]
2. Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Sinoquet L; Jacot W; Gauthier L; Pouderoux S; Viala M; Cayrefourcq L; Quantin X; Alix-Panabières C
Clin Chem; 2021 Nov; 67(11):1503-1512. PubMed ID: 34355741
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
[TBL] [Abstract][Full Text] [Related]
5. Efficacy relevance of PD-L1 expression on circulating tumor cells in metastatic breast cancer patients treated with anti-PD-1 immunotherapy.
Zhou Y; Zhou J; Hao X; Shi H; Li X; Wang A; Hu Z; Yang Y; Jiang Z; Wang T
Breast Cancer Res Treat; 2023 Jul; 200(2):281-291. PubMed ID: 37227611
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
7. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Nicolazzo C; Raimondi C; Mancini M; Caponnetto S; Gradilone A; Gandini O; Mastromartino M; Del Bene G; Prete A; Longo F; Cortesi E; Gazzaniga P
Sci Rep; 2016 Aug; 6():31726. PubMed ID: 27553175
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Koh Y; Yagi S; Akamatsu H; Kanai K; Hayata A; Tokudome N; Akamatsu K; Higuchi M; Kanbara H; Nakanishi M; Ueda H; Yamamoto N
Clin Lung Cancer; 2019 Jul; 20(4):270-277.e1. PubMed ID: 31005568
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial.
Gennari A; Foca F; Zamarchi R; Rocca A; Amadori D; De Censi A; Bologna A; Cavanna L; Gianni L; Scaltriti L; Rossi E; Facchinetti A; Martini V; Bruzzi P; Nanni O
Breast Cancer Res Treat; 2020 May; 181(1):61-68. PubMed ID: 32200486
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
[TBL] [Abstract][Full Text] [Related]
11. Investigating Radiotherapy Effects on PD-L1 Expression in Circulating Tumor Cells: An Exploratory Study.
Rafli R; Harahap WA; Gondhowiardjo S; Ekaputra A
Asian Pac J Cancer Prev; 2024 May; 25(5):1559-1566. PubMed ID: 38809627
[TBL] [Abstract][Full Text] [Related]
12. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
13. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Satelli A; Batth IS; Brownlee Z; Rojas C; Meng QH; Kopetz S; Li S
Sci Rep; 2016 Jul; 6():28910. PubMed ID: 27363678
[TBL] [Abstract][Full Text] [Related]
14. Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
Chen YL; Huang WC; Lin FM; Hsieh HB; Hsieh CH; Hsieh RK; Chen KW; Yen MH; Lee J; Su S; Marfatia T; Chang SE; Sundar P; Patterson B; Watson D; Mei R; Javey M
Cancer Immunol Immunother; 2019 Jul; 68(7):1087-1094. PubMed ID: 31089757
[TBL] [Abstract][Full Text] [Related]
15. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
[TBL] [Abstract][Full Text] [Related]
16. Frequent expression of PD-L1 on circulating breast cancer cells.
Mazel M; Jacot W; Pantel K; Bartkowiak K; Topart D; Cayrefourcq L; Rossille D; Maudelonde T; Fest T; Alix-Panabières C
Mol Oncol; 2015 Nov; 9(9):1773-82. PubMed ID: 26093818
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
[TBL] [Abstract][Full Text] [Related]
18. Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies.
Tan Z; Yue C; Ji S; Zhao C; Jia R; Zhang Y; Liu R; Li D; Yu Q; Li P; Hu Z; Yang Y; Xu J
Oncologist; 2021 Dec; 26(12):e2227-e2238. PubMed ID: 34516729
[TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Kennedy LC; Lu J; Kuehn S; Ramirez AB; Lo E; Sun Y; U'Ren L; Chow LQM; Chen Z; Grivas P; Kaldjian EP; Gadi VK
Target Oncol; 2022 May; 17(3):329-341. PubMed ID: 35696014
[TBL] [Abstract][Full Text] [Related]
20. Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.
Moku P; Shepherd L; Ali SM; Leitzel K; Parulekar WR; Zhu L; Virk S; Nomikos D; Aparicio S; Gelmon K; Drabick J; Cream L; Halstead ES; Umstead TM; Mckeone D; Polimera H; Maddukuri A; Ali A; Nagabhairu V; Poulose J; Pancholy N; Spiegel H; Chen BE; Lipton A
Cancer; 2020 Nov; 126(22):4859-4866. PubMed ID: 32910476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
